Notable markers include S100B and lactate dehydrogenase (LDH), already partially integrated into clinical practice, and new candidates like melanoma-inhibiting activity (MIA), osteopontin, and tumor-associated antigen 90 immune complex (TA90-IC), which offer predictive capabilities for treatment outcomes. The gene discussed is SPP1; the disease is melanoma.